Raaphorst G P, Ko D, Feeley M M, Danjoux C E, Maroun J, Evans W K
Ottawa Regional Cancer Centre, Ontario, Canada.
Anticancer Res. 1991 Jan-Feb;11(1):41-7.
Two non small cell lung cancer (NSCLC) cell lines were tested in vitro to evaluate the effect of lonidamine, cisplatin and combinations of these two agents using different doses and schedules. Lonidamine alone at concentrations greater than 50 micrograms/ml caused inhibition of cell growth in both monolayer and spheroid cell cultures. Cisplatin at concentrations of 10-20 microM caused a concentration dependent toxicity and inhibited growth in monolayer and spheroid cell cultures. Combination treatment of lonidamine and cisplatin caused concentration dependent effects. For 25 micrograms/ml lonidamine, there was no additive and in some cases an antagonistic effect when used with cisplatin. For higher lonidamine concentrations (75 and 100 micrograms ml), an additive effect with cisplatin (10-15 microM) was observed. This effect saturated for cisplatin concentrations of 20 microM. These data show some potential for lonidamine and cisplatin combination therapy but treatment doses and schedules will have to be identified so that the additive effect can be achieved at concentrations clinically attainable.
对两种非小细胞肺癌（NSCLC）细胞系进行了体外测试，以评估氯尼达明、顺铂以及这两种药物不同剂量和给药方案组合的效果。单独使用浓度大于50微克/毫升的氯尼达明会抑制单层和球体细胞培养中的细胞生长。浓度为10 - 20微摩尔的顺铂会产生浓度依赖性毒性，并抑制单层和球体细胞培养中的生长。氯尼达明和顺铂联合治疗产生浓度依赖性效应。对于25微克/毫升的氯尼达明，与顺铂联用时没有相加作用，在某些情况下甚至有拮抗作用。对于更高的氯尼达明浓度（75和100微克/毫升），观察到与顺铂（10 - 15微摩尔）有相加作用。当顺铂浓度为20微摩尔时，这种作用达到饱和。这些数据表明氯尼达明和顺铂联合治疗有一定潜力，但必须确定治疗剂量和给药方案，以便在临床可达到的浓度下实现相加作用。
